Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) Jump more than 12% on News of First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir Announcement

Shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) Jump more than 12% on News of First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir Announcement

Immunooncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, Argos Therapeutics, Inc. (NASDAQ:ARGS), today announced that they a patient in the Phase 2 HIV eradication trial at the University of North Carolina has been dosed with a therapy utilizing RNA antigens from the patient’s latent viral reservoir.  Shares vaulted over 12% on the news. DURHAM, N.C., Sept. 06, 2017 (GLOBE […]

Read More ˃